| |
Newsroom /
Health and Fitness
/
Healthcare
/
Head and Neck Cancer – Drug Pipeline Analysis and Market Forecasts to 2016
Head and Neck Cancer – Drug Pipeline Analysis and Market Forecasts to 2016
Head and Neck Cancer Market is Market is Estimated to Roughly Double in Size by 2016
Hyderabad,
AP,
India
(prbd.net)
23/01/2010
"Head and Neck Cancer – Drug Pipeline Analysis and Market Forecasts to 2016"
GlobalData expects the global head and neck cancer market to grow at 8.3% annually for the next seven years to reach $1,809m by 2016. It was valued at $1,035m in 2009. This significant growth is primarily attributed to the high incidence, prevalence and diagnosis rate of the disease and the high prescription rates of the currently approved products. In addition, the successful launch of certain biologics, gene therapies and vaccines such as Reolysin, Oncovex and nimotuzumab, currently in Phase III, may significantly stimulate market growth in the near future. However, the low treatment seeking rate and the widespread use of off-label drugs will act as barriers for market growth.
GlobalData’s analysis has found that the current competition in the head and neck cancer market is weak. The competitive landscape is sparsely populated with only two FDA-approved products. The market is characterized by high off-label usage of drugs such as cisplatin, paclitaxel carboplatin and combinations. The currently marketed products are not highly efficacious and so are not able to meet market demands such as improved five-year survival rates, reductions in tumor sizes and the control of tumor recurrence. However, the development of technologically advanced products such as vaccines, gene therapy and biologics in different stages of the pipeline promises to provide better options for treatment.
The current head and neck cancer market is faintly competitive with only two approved products, the last of which was approved in 2004. Other marketed products, such as clisplatin, paclitaxel and carboplatin, are used as off-label drugs. This clearly indicates that the market is currently faced with a high level of unmet needs in terms of safety and efficacy. The efficacy of the currently marketed products (Taxotere and Erbitux) is moderate in terms of the management of the disease. Erbitux has a better safety profile than Taxotere, which is associated with serious adverse events. However, both of the marketed products have some serious side effects such as neutropenia, anemia, severe hypersensitivity, serious infusion reactions, cardiopulmonary arrests and severe fluid retention.
Because current therapeutic landscape lacks drugs with first-rate safety and efficacy profiles, the market continues to present opportunities for stronger pipeline candidates. The extent of unmet needs in the head and cancer market is considered to be high and can be fulfilled by technologically-advanced products with improved safety and efficacy profiles.
GlobalData, the industry analysis specialist, has released its new report, “Head and Neck Cancer – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global head and neck cancer market. The report identifies the key trends shaping and driving the global head and neck cancer market. It also provides insights on the current competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. More importantly, the report gives valuable insights on the pipeline products within the global head and neck cancer sector.
Or Visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|